Black Diamond Therapeutics To Present Results From Phase 2 Clinical Study Of Silevertinib On Dec. 3

Benzinga · 3d ago

Black Diamond Therapeutics, Inc. (NASDAQ:BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, will host a webcast to present results from its Phase 2 clinical trial of silevertinib and provide a program update on Wednesday, December 3, 2025, at 8:00am ET.